William Morwa Reagile Matshe

William Morwa Reagile Matshe

Auto-generated profile, based on publicly available information

William Morwa Reagile Matshe

Bio‐polymer Modification and Advanced Therapeutics Laboratory, Centre For Nanostructures and Advanced Materials CSIR Pretoria Gauteng South Africa

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2019 in International Journal of Polymeric Materials and Polymeric Biomaterials
Verified
Journal Article
Closed access
Blessing AderibigbeBlessing Aderibigbe
Blessing Aderibigbe
Tobeka NakiTobeka Naki
Tobeka Naki
Vanessa SteenkampVanessa Steenkamp
Vanessa Steenkamp
MNMutshinyalo Nwamadi
Mutshinyalo Nwamadi
Suprakas Sinha RaySuprakas Sinha Ray
Suprakas Sinha Ray
WMWilliam Morwa Reagile Matshe
William Morwa Reagile Matshe
Platinum-based drugs are potent anticancer drugs and are effective for the treatment of various cancers. However, they are limited pharmacologically due to toxic side effects, drug resistance and poor water solubility. In order to overcome these limitations, platinum was incorporated onto polyamidoamine carriers together with alendronate and procaine hydrochloride to form a series of conjugates. Cytotoxicity was assessed using the sulforhodamine B assay on MCF-7, MDA-MB-231 and EA.hy926 cell lines. The polymer-drug conjugates showed cytotoxicity which was selective to the cancer cell lines. The free drugs decreased cell density in all cell lines and were nonspecific. These findings indicate that the incorporation of bioactive agents onto polymers can overcome cytotoxicity associated with the drugs. The selective inhibitory effects of the conjugates towards the cancer cell lines suggest that these conjugates are potential therapeutics for combination therapy.

14 April 2023 in Macromolecular Bioscience
Verified
Journal Article
Open access
WMWilliam M.R. Matshe
William M.R. Matshe
LTLesego L. Tshweu
Lesego L. Tshweu
SMSindisiwe Mvango
Sindisiwe Mvango
ZCZamani E.D. Cele
Zamani E.D. Cele
ACAvashnee S. Chetty
Avashnee S. Chetty
MBMohammed Balogun
Mohammed Balogun
Uncomplicated malaria is effectively treated with oral artemisinin‐based combination therapy (ACT). Yet, there is an unmet clinical need for the intravenous treatment of the more fatal severe malaria. There is no combination intravenous therapy for uncomplicated due to the nonavailability of a water‐soluble partner drug for the artemisinin, artesunate. The currently available treatment is a two‐part regimen split into an intravenous artesunate followed by the conventional oral ACT . In a novel application of polymer therapeutics, the aqueous insoluble antimalarial lumefantrine is conjugated to a carrier polymer to create a new water‐soluble chemical entity suitable for intravenous administration in a clinically relevant formulation . The conjugate is characterized by spectroscopic and analytical techniques, and the aqueous solubility of lumefantrine is determined to have increased by three orders of magnitude. Pharmacokinetic studies in mice indicate that there is a significant plasma release of lumefantrine and production its metabolite desbutyl‐lumefantrine (area under the curve of metabolite is ≈10% that of the parent). In a Plasmodium falciparum malaria mouse model, parasitemia clearance is 50% higher than that of reference unconjugated lumefantrine. The polymer‐lumefantrine shows potential for entering the clinic to meet the need for a one‐course combination treatment for severe malaria.

28 September 2025 in Applied Research
Verified
Journal Article
Open access
WMWilliam Matshe
William Matshe
SMSindisiwe Mvango
Sindisiwe Mvango
RMRudzani Malabi
Rudzani Malabi
ATAsongwe Lionel Ateh Tantoh
Asongwe Lionel Ateh Tantoh
CACharlene Andraos
Charlene Andraos
MBMohammed Balogun
Mohammed Balogun
Malaria is treatable with several combinations of drugs, the most well‐known and currently most effective being artemisinin‐based therapies. Gastrointestinal absorption of these drugs can be poor and erratic if not taken with a fatty meal. Nausea and the loss of appetite, common symptoms of even mild malaria, can therefore jeopardize the effectiveness of the treatment. To enhance the bioavailability of artemisinin‐based combination therapies, several lipid‐based formulations and delivery systems have been investigated. In this study, we synthesized oligochitosan conjugates of the antimalarial drugs dihydroartemisinin and lumefantrine and examined their physical stability and biological activities. The hydrodynamic properties of both conjugates varied unpredictably under pH conditions like those found at different stages along the gastrointestinal tract and in plasma. The viability of Caco‐2 cells exposed to the conjugates was also investigated in comparison to the free drugs. Both conjugates demonstrated significantly lower cytotoxicity compared to the free drugs at concentrations up to 0.5 mg/mL, particularly during the first 24 h of exposure. Despite this, they retained their antiplasmodial effect against Plasmodium falciparum in an in vitro assay at 1 µg/mL and 5 µg/mL. These new chitosan biomaterials hold great potential for further development into oral therapeutics that would not require fatty meal intake due to the intrinsic mucoadhesiveness of chitosan.

12 February 2026 in Advanced Therapeutics
Verified
Journal Article
Open access
TGThenesia R. Govender
Thenesia R. Govender
WMWilliam M. R. Matshe
William M. R. Matshe
NDNokuthula Dube
Nokuthula Dube
ZCZamani E. D. Cele
Zamani E. D. Cele
AWAurelia Alvina Williams
Aurelia Alvina Williams
MBMohammed Balogun
Mohammed Balogun
Polymer–drug conjugates have seen limited exploration in antimalarial therapy, despite their successful development for cancer and other diseases. With rising resistance and a critical shortage of first‐line treatments for severe malaria, innovative drug delivery strategies are urgently needed to maximize the currently available drugs. Building on our previous work that demonstrated a water‐soluble polymer–lumefantrine conjugate for the intravenous treatment of severe malaria, we investigated the influence of linker chemistry on drug release rate and kinetics of a new polyethylene glycol‐lumefantrine conjugate under conditions relevant to malaria pathophysiology. Four homologous aliphatic diacid linkers (succinic, glutaric, adipic, and dodecanedioic acids) containing 4, 5, 6, and 12 carbon atoms, respectively, were introduced between the polymer and the drug. The conjugates were structurally well‐defined and selectively cleaved at the ester bond under acidic conditions (pH 5.5), releasing only free lumefantrine, while remaining stable in human plasma (pH 7.4). Drug release rates were inversely proportional to linker length, with only the succinic acid‐linked conjugate, which exhibited an initial burst release, deviating from first‐order kinetic models. Complete inhibition of the Plasmodium falciparum NF54 strain was observed in vitro with a divalent variant of the succinic acid‐linked conjugate, underscoring its potential for effective therapeutic action.